Tenofovir associated with increased risk of kidney disease
Limited evidence that vitamin D supplements of any benefit for patients with HIV
Europeans find high prevalence of lipodystrophy in HIV-positive children
Raltegravir kinder to bones and body fat than boosted protease inhibitors in Spanish trial
Product information for raltegravir updated to warn of Stevens Johnson syndrome and hypersensitivity reaction
Growing pain
A fifth of patients discontinue Atripla within a year, CNS side-effects the main reason
Raltegravir combined with Kaletra associated with good preservation of bone density over 96 weeks
Doubt remains if HIV therapy increases the risk of fragility fractures
